Recombinant Human YTH domain-containing family protein 1 (YTHDF1)

Function

Specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, and regulates their stability (PubMed:24284625, PubMed:26318451, PubMed:32492408, PubMed:39900921). M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing (PubMed:24284625, PubMed:32492408). Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex (PubMed:32492408). The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) shares m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation (PubMed:28106072, PubMed:32492408). Required to facilitate learning and memory formation in the hippocampus by binding to m6A-containing neuronal mRNAs (By similarity). Acts as a regulator of axon guidance by binding to m6A-containing ROBO3 transcripts (By similarity). Acts as a negative regulator of antigen cross-presentation in myeloid dendritic cells (By similarity). In the context of tumorigenesis, negative regulation of antigen cross-presentation limits the anti-tumor response by reducing efficiency of tumor-antigen cross-presentation (By similarity). Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation (PubMed:31292544, PubMed:31388144, PubMed:32451507). The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules (PubMed:31292544)

Subcellular Location

Cytoplasm; Cytoplasm, P-body; Cytoplasm, Stress granule

Subunit

Interacts with CNOT1; promoting recruitment of the CCR4-NOT complex (PubMed:32492408). Interacts with ribosomes (PubMed:26046440). Interacts with eIF3 (EIF3A or EIF3B) (PubMed:26046440). Interacts with YTHDF3 (PubMed:28106072)

• Ota T. et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. — Nat. Genet. (2004)
• Deloukas P. et al. The DNA sequence and comparative analysis of human chromosome 20. — Nature (2001)
• The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). — Genome Res. (2004)
• Onouchi H. et al. Dermatomyositis associated with cancer autoantigen. (FEB-)
• Bechtel S. et al. The full-ORF clone resource of the German cDNA consortium. — BMC Genomics (2007)
• Daub H. et al. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. — Mol. Cell (2008)
• Dephoure N. et al. A quantitative atlas of mitotic phosphorylation. — Proc. Natl. Acad. Sci. U.S.A. (2008)
• Gauci S. et al. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. — Anal. Chem. (2009)